
Developing next-generation CB1 blockade therapies for metabolic disease.
Inversago Pharma specialized in CB1 receptor blockade therapies for metabolic disorders. Acquired by Novo Nordisk in August 2023.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.